Qualigen Therapeutics Inc banner

Qualigen Therapeutics Inc
F:7R9B

Watchlist Manager
Qualigen Therapeutics Inc Logo
Qualigen Therapeutics Inc
F:7R9B
Watchlist
Price: 0.1722 EUR -11.42% Market Closed
Market Cap: €6.7m

Wall St Price Targets

7R9B Price Targets Summary
Qualigen Therapeutics Inc

There are no price targets for 7R9B.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Qualigen Therapeutics Inc Competitors:
Price Targets
CSGP
CoStar Group Inc
61% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Qualigen Therapeutics Inc

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Qualigen Therapeutics Inc

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-100%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-100%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 7R9B's stock price target?
Not Available

7R9B does not have any price targets made by Wall Street professionals.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett